Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Iqvia Holdings Inc.

NYSE: IQV · Industrial Applications and Services · 4 alerts · CIK 1478242

Share price
$264.73Close, Nov 16
Market cap
$43.6B
Shares outstanding
164.8MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Iqvia Holdings Inc. filings on SEC EDGAR ↗

7:42 PM ET Form 4
Insider Selling

Iqvia Holdings Insider Eric Sherbet Sells $1.24M of Stock

Eric Sherbet sold 4,446 shares of Iqvia Holdings Inc. at $278.83 a share, worth $1.24M in total on Nov 9, 2026. Shares held after the trade: 24,989 (-15.1%).

Value
$1.24M
Shares
4,446
Price
$278.83
Holding change
-15.1%
Trade date
Nov 9, 2026
5:08 PM ET 10-Q
Financial Results

Iqvia Holdings Q3 2026 Results: Net Income $350M, Up 5.7% YoY

IQVIA reported third-quarter 2026 revenues of $4.43 billion, an 8% increase year-over-year, with net income attributable to the company rising to $350 million. For the first nine months of 2026, the company generated $2.0 billion in net cash from operating activities and utilized $950 million for common stock repurchases.

Key figure
Net income $350M · +5.7% YoY
7:09 AM ET 8-K
Financial Results

Iqvia Holdings Financial Results

IQVIA reported third-quarter 2026 revenue of $4.43 billion, up 8.0% year-over-year, driven by strong growth in R&D Solutions and Commercial Solutions. The company achieved record clinical bookings of $3.2 billion and raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS.

“IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations. Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable.”

Ari Bousbib, chairman and CEO of IQVIA
5:03 PM ET 8-K
Loan & Debt

Iqvia Holdings $2B Debt Financing with U.S. Bank Trust Company, National Association

IQVIA Inc., a subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2.0 billion in 6.375% senior notes due 2034. The proceeds will be used to redeem existing 5.000% notes due 2026, repay revolving credit facility debt, and cover offering expenses.

Value
$2B
Counterparty
U.S. Bank Trust Company, National Association
Term
through March 2034

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.